anyone else notice phase 2 kicking in around week 30
Something I noticed reading old threads that I have not seen said out loud.
The advice on TRIUMPH in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the same confidence.
I have listed what I think the current consensus is below. Correct me — that is the point of posting it.
best — the order this archive was captured in
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
This is correct. Triple agonism is genuinely different.
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
the dosing is steep, the constipation reports are real, and nobody knows the human safety yet
Not to be pedantic but triple agonist and glucagon are being used interchangeably and they are not interchangeable in real life.
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
the dosing is steep, the constipation reports are real, and nobody knows the human safety yet
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.
Slight fix: the number was 99.1, not 93.7. Decimal point, but a fairly consequential one.
Retitled to remove editorialising. Put the evidence in the body.
Respectfully this is a sample of one presented as a finding.
What was the dosing schedule in that arm?
retatrutide is not approved anywhere for human use, posts must not read as instructions
research use only, handling and analysis, not protocols
research use only, handling and analysis, not protocols
Disagree on that part. 98.1% and 97.9% on the same vial is normal.
heart rate and dose escalation need actual measurements, not impressions
retatrutide is not approved anywhere for human use, posts must not read as instructions
The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
TRIUMPH data is phase 2, not phase 3, smaller n and shorter
This is correct. Triple agonism is genuinely different.
heart rate and dose escalation need actual measurements, not impressions
the dosing is steep, the early fullness reports are real, and nobody knows the human safety yet
Which trial arm and what was the n?
The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.
research use only, handling and analysis, not protocols
TRIUMPH data is phase 2, not phase 3, smaller n and shorter
- 1the dosing is steep, the constipation reports are real, and nobody knows the…7 comments in this branch · started by u/helga_vermeulen
- 2The practical rule people converge on is 28 days at fridge temperature after…7 comments in this branch · started by u/incretin_ivy